CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 488]

• Reactivity: Mu
• Applications: WB, ELISA(Cap), ELISA(Det)
• Clone: 115705
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 488

CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse CD30/TNFRSF8
  Phe19-Thr281
  Accession # Q60846
• Specificity: Detects mouse CD30/TNFRSF8 in ELISAs and Western blots. In sandwich immunoassays, no cross-reactivity or interference with recombinant mouse (rm) TNF RI/TNFRSF1A, recombinant human (rh) TNF RI/TNFRSF1A, rhTNF RII/TNFRSF1B, rmTNF‑ alpha /TNFSF2, rhTNF‑
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 488]

• CD30 antigen
• CD30
• CD30KI-1
• CD30L receptor
• cytokine receptor CD30
• D1S166EKi-1
• Ki-1 antigen
• Lymphocyte activation antigen CD30
• TNFRSF8
• tumor necrosis factor receptor superfamily member 8
• tumor necrosis factor receptor superfamily, member 8

Background

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature mouse CD30 consists of a 264 amino acid (aa) extracellular domain (ECD) with three cysteine-rich repeats, a 27 aa transmembrane segment, and a 190 aa cytoplasmic domain (3). In contrast, human CD30 includes an additional 90 aa in the ECD and contains six cysteine-rich repeats. Within common regions of the ECD, mouse CD30 shares 53% and 80% aa sequence identity with human and rat CD30, respectively. CD30 is normally expressed on antigen‑stimulated Th cells and B cells (4‑6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen‑induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4⁺CD8⁺ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85‑90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.